Shared on15 Aug 25
Marchex’s modestly higher future P/E ratio and slight weakening in net profit margin suggest incrementally greater valuation risk, but the consensus price target remains unchanged at $4.00. What's in the News Marchex launched an AI-powered healthcare solution to provide health systems and marketing organizations with actionable insights from patient conversations, enhancing attribution, appointment prioritization, and marketing optimization.
Shared on17 Apr 25Fair value Increased 24%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.